PF 4840082Alternative Names: PF-04840082; PF-4840082
Latest Information Update: 15 May 2012
At a glance
- Originator Pfizer
- Class Monoclonal antibodies; Osteoporosis therapies
- Mechanism of Action DKK1 protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Osteoporosis
Most Recent Events
- 10 May 2012 Discontinued - Phase-I for Osteoporosis in USA (IV)